Objectives-To assess (a) the prevalence of microalbuminuria in patients with rheumatoid arthritis, (b) the association between urinary albumin excretion and disease activity as estimated by the erythrocyte sedimentation rate and C reactive protein (CRP), and (c) the association between urinary albumin excretion and treatment with antirheumatic drugs. Methods-Sixty five patients with rheumatoid arthritis attending two rheumatology clinics were compared with 51 control subjects matched by age and sex. The controls consisted of 20 healthy subjects, 16 patients with osteoarthritis and 15 with non-articular rheumatism. Patients with hypertension, diabetes mellitus, or evidence of previous renal disease were not included. Urinary albumin was assayed by inumunoturbidimetry in random urine samples on two occasions within seven months. The results were expressed as the ratio of urinary albumin to urinary creatinine ratio. Disease activity was assessed by the erythrocyte sedimentation rate and CRP. A drug history for the year before entry to the study was obtained for each patient. Results-Urinary albumin to creatinine ratio in patients with rheumatoid arthritis was significantly greater than in controls (p <0.01). Microalbuminuria (urinary albumin to creatinine ratio 3-30 mg/mmol in either or both urine samples) was present in 27.7% of patients with rheumatoid arthritis and 7-8% of the control subjects. A significant relation was noted between urinary albumin to creatinine ratio and CRP, and the duration of disease. The number of patients treated with either gold or penicillamine was significantly greater in patients with microalbuminuria than in patients with normoalbuminuria.
present in 27 .7% of patients with rheumatoid arthritis and 7-8% of the control subjects. A significant relation was noted between urinary albumin to creatinine ratio and CRP, and the duration of disease. The number of patients treated with either gold or penicillamine was significantly greater in patients with microalbuminuria than in patients with normoalbuminuria. Conclusions-Microalbuminuria is frequently present in patients with rheumatoid arthritis. Treatment with gold and penicillamine seems to increase the risk of developing microalbuminuria. Urinary albumin measured by immunochemical methods is a simple and sensitive test to detect early subclinical renal dysfunction and drug induced renal damage in rheumatoid arthritis. Urinary albumin excretion was found to be significantly correlated with CRP and may be a sensitive indicator of disease activity in patients with rheumatoid arthritis.
(Ann Rheum Dis 1995; 54: [189] [190] [191] [192] Microalbuminuria has been defined as an increased excretion of albumin above the reference range for healthy subjects which is undetectable by dipstick testing.' It is associated with a generalised vascular damage in patients with diabetes mellitus and is a predictor of diabetic nephropathy.2 3 In nondiabetic populations, microalbuminuria has been found with a prevalence ranging from 6.3% to 13%.4 Further longitudinal studies are required to elucidate the long term renal prognosis in non-diabetic subjects with the condition. However, increased urinary albumin excretion is associated with hypertension, cardiovascular disease, and increased mortality rate,5-7 and has also been reported in patients with rheumatic diseases other than rheumatoid arthritis (RA), such as systemic lupus erythematosus8 9 and systemic sclerosis. '0
In patients with RA there is a high prevalence of renal impairment, with evidence of reduced glomerular filtration and tubular function.""-13 Various morphological findings in the kidneys have been described" 14 15 and renal disease is presumed to be a frequent cause of death in RA.'6 '7 It would be useful, therefore, to identify those at risk of developing clinical nephropathy, and sensitive measures of renal function should be available. In RA, glomerular proteinuria has been considered as a complication of advanced disease caused by the direct effects of the disease on the kidney, or the action of nephrotoxic drugs, or both. However, subclinical renal dysfunction is not uncommon in RA, and many of these patients with incipient nephropathy are not detected by routine laboratory tests such as assays for urine total protein or Albustix.1' "9 The advent of assays sensitive and specific for urinary albumin has enabled the detection of glomerular abnormalities at an earlier stage in patients without clinical renal involvement. 20 Patients at risk of developing renal dysfunction might therefore be detected earlier by the appearance of microalbuminuria. Furthermore, increased urinary excretion of albumin may reflect not only glomerular disease, but also the inflammatory state and disease activity. The aim of the present study was In the present study, most patients were treated with NSAIDs, often combined with DMARDs. Treatment with penicillamine and gold was associated significantly with microalbuminuria. These findings are consistent with other studies suggesting that these drugs are important contributors to proteinuria and microalbuminuria in patients with RA.32 Because of the complexity of rheumatoid drug histories, it is difficult to correlate results with individual drug treatments and only a few of the patients in our study did not receive antirheumatic drugs. We cannot, therefore, conclude from our results if microalbuminuria is solely a drug induced side effect.
It has been suggested that changes in renal permeability to plasma proteins reflect increased systemic vascular permeability in acute inflammatory conditions.33 Thus the urinary excretion of albumin may reflect a systemic reaction in the acute phase response.34
In our study a highly significant correlation between CRP and urinary excretion of albumin was demonstrated. However, the correlation with ESR was not significant. The latter is partially explained by some patients with normoalbuminuria who had increased values of ESR for reasons other than RA; it may also reflect a low sensitivity of ESR as a marker of disease activity. Microalbuminuria was associated with the duration of disease. The possible correlation between urinary excretion of albumin, disease activity, and duration of RA may be explained in two ways: either severe and long standing RA tends to affect the kidneys and the systemic vascular permeability more, or patients with more severe and long standing disease receive more nephrotoxic treatment. Urine analyses reflecting renal tubular function have been shown to correlate with disease activity in RA. " We have found an association between urinary excretion of albumin and CRP, but further investigations are required using more sensitive indicators of disease activity.
In conclusion, microalbuminuria and subclinical renal damage are frequent in RA, particularly in those with long standing disease. A subclinical renal involvement may not be revealed by routine laboratory tests such as serum creatinine. Our results suggest that microalbuminuria is a more sensitive predictor of renal dysfunction in patients at risk. Its measurement may serve as a useful tool for the management of patients with RA but without clinical nephropathy. However, the long term renal prognosis in patients with microalbuminuria requires clarification in longitudinal studies. We believe that in the majority of patients with microalbuminuria in RA, the problem is reversible and rarely develops to end stage renal failure. The effects of many antirheumatic drugs on glomerular and tubular function can be of clinical importance and should be monitored with sensitive methods. We recommend immunological methods measuring urinary excretion of albumin as a routine procedure to detect glomerular involvement in its initial phase in order to devise the most appropriate treatment in patients with RA. Further studies are recommended to clarify a possible association between urinary excretion of albumin and disease activity, and to evaluate microalbuminuria as an indicator of the long term prognosis in RA.
